Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis - Full Text View

Sponsor:	M.D. Anderson Cancer Center
Collaborator:	Pfizer
Information provided by:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00904995

Purpose

Objectives:

To investigate the relationship between the administration of intravenous (IV) and oral voriconazole (vori) and the occurrence of false positive (1,3) beta-d- glucan (BG) relative to the standard assessment criteria used to diagnose invasive fungal infection in patients with hematologic malignancies.

Condition	Intervention	Phase
Leukemia Fungal Infection	Drug: Voriconazole	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Kinetics of 1, 3 Beta-d- Glucan Assay in Patients With Hematologic Malignancies Receiving Voriconazole Prophylaxis

Resource links provided by NLM:

MedlinePlus related topics: Cancer Fungal Infections Leukemia Molds

Drug Information available for: Voriconazole

U.S. FDA Resources

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:

Percentage of Samples With BG Levels > 60pg/ml [ Time Frame: Up to 42 days ] [ Designated as safety issue: No ]
Rate calculated as number of participants with positive levels divided by total number of participants. beta-d-glucan (BG), a cell wall constituent of fungi, can be detected in serum as a marker of Invasive fungal infections (IFI).

Blood samples were drawn on first 2 days of treatment at baseline (before the drug) and at 1, 2, 4, 8 hours after the first dose of the day. BG serum levels were measured using the Fungitell assay, using a cut off value of 60 pg/ml for positivity.

Enrollment:	23
Study Start Date:	May 2009
Study Completion Date:	July 2010
Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Group 1 - Oral Voriconazole Starting oral dose of 400 mg pills twice a day for first day, followed by 200 mg by mouth twice a day thereafter.	Drug: Voriconazole Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter. Other Name: Vfend
Experimental: Group 2 - IV + Oral Voriconazole 6 mg/kg by vein (IV) first dose then 200 mg pills two times a day thereafter.	Drug: Voriconazole 6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter. Other Name: Vfend

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of hematologic malignancy with indication to receive antifungal prophylaxis.
Age >/= 18 years.
Patients must sign an informed consent.

Exclusion Criteria:

Patients with history of anaphylaxis attributed to azole compounds: voriconazole, itraconazole, fluconazole, posaconazole
Patients with clinical or other evidence that indicates that they have proven or probable invasive fungal infection prior to enrollment (European Organisation for Research and Treatment of Cancer (EORTC) criteria).
Patients with total bilirubin levels > 3 times the upper normal limits (i.e. > 3.0 mg/dl); or aspartate aminotransferase (AST or SGOT) or alanine aminotransferase (ALT or SGPT)> 5 times upper limit normal.
Patients receiving any medication that is contraindicated with the use of voriconazole. Voriconazole is contraindicated with the co-administration of the following drugs:sirolimus, terfenadine, astemizole, cisapride, pimozide, quinidine, ergot alkaloids, rifabutin, rifampin, high-dose ritonavir (400 mg Q12h), carbamazepine, long-acting barbiturates, efavirenz (with standard dose vfend and efavirenz), St. John's Wort.
Patients currently receiving voriconazole for antifungal prophylaxis.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00904995

Locations

United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

Pfizer

Investigators

Study Chair:

Jorge Cortes, MD

UT MD Anderson Cancer Center

More Information

Additional Information:

UT MD Anderson Cancer Center website This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Jorge Cortes, MD / Professor, UT MD Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00904995 History of Changes
Other Study ID Numbers:	2008-0443
Study First Received:	May 18, 2009
Results First Received:	April 18, 2011
Last Updated:	June 3, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:

Leukemia
Cancer of the blood
Cancer of the bone marrow
Hematologic malignancy

Invasive fungal infection
Voriconazole
Vfend
antifungal prophylaxis

Additional relevant MeSH terms:

Leukemia
Mycoses
Hematologic Neoplasms
Neoplasms by Histologic Type
Neoplasms
Neoplasms by Site
Hematologic Diseases
Voriconazole

Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
14-alpha Demethylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on February 09, 2012